Dorrapharma is a comprehensive pharmaceutical group integrating R&D, manufacture and sales of pharmaceutical APIs and intermediates, cosmetic ingredients, veterinary drug ingredients, formulations and etc. We own the core technology advantage in the area of bromination, enzyme/metalcatalyzed, nitration and hydrogenation, and obtain multiple core patents for invention. We stick to raising the value both for the company and customers...
MORE
At present, Dorra has two R&D centers, Nanjing R&D Center and Taizhou R&D Center, which are located in Nanjing Jiangbei New District, the first national new district in Jiangsu Province, New Materials Life Science Park, and Taizhou City, Zhejiang Province, with a total area of 6000 square meters...
Dorra Pharma currently has three production bases which are located at the Grade D industrial Park in Hubei and Gansu Province with total reactor capacity of 3,000 m3. The quality system are approved by NMPA/PMDA/US FDA, offering key starting material, GMP intermediates, APIs and CDMO services.
MORE
Dorra Pharma is proud to announce that its self-developed core active ...
On June 24, 2025, PTC Therapeutics, Inc. (NASDAQ: PTCT) announced that Sephienc...
Copyright Nanjing Dorra Pharmaceutical Technology Co.,Ltd. @ 2018 China All Rights Reserved 蘇ICP備12056923號-1
Tel: 025-82232955 025-82232966
Fax:025-82232933 025-82232944
E-mail: info@dorrapharma.com
